Aktienanalyse zu CG Oncology Inc (CGON)CGONCG Oncology Inc

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

CG Oncology Inc is currently a hold. The stock is priced at $74.34, which is below the average analyst price target of $85 from Truist, indicating potential upside. However, the RSI is at 35.068, suggesting the stock is oversold, and the recent 5-day change is down by 6.85%, indicating negative momentum. The main risk is the significant net loss of $79,056,000 reported in Q2 2026, which raises concerns about profitability and financial stability.